NCT00033358: Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer |
|
|
| Completed | 2 | 52 | US | medroxyprogesterone, Depo-Provera, medroxyprogesterone acetate, MPA, Provera, Provera Dosepak, ethinyl estradiol, Diogyn E, EE, Estinyl, Ethinoral, Eticylol, norgestrel, Microlut, NORGES, Ovrette, Wy-3707, laboratory biomarker analysis | National Cancer Institute (NCI) | Endometrial Cancer | 10/07 | | | |
NCT00064025: Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus |
|
|
| Completed | 2 | 75 | US | Laboratory Biomarker Analysis, Medroxyprogesterone, Curretab, Therapeutic Conventional Surgery | Gynecologic Oncology Group, National Cancer Institute (NCI) | Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Recurrent Uterine Corpus Carcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer | 09/10 | | | |
